AG˹ٷ

STOCK TITAN

[Form 4] Shake Shack Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has filed a Rule 424(b)(5) prospectus supplement establishing a US$50 million at-the-market (ATM) equity program through A.G.P./Alliance Global Partners. Under the July 3 2025 Sales Agreement, A.G.P. will act as sales agent on a best-efforts basis and receive a 3.0% commission on gross proceeds. No minimum drawdown is required and proceeds will not be placed in escrow.

The facility allows Tevogen to issue primary common shares (par $0.0001) from time to time at prevailing market prices. At the July 2 2025 closing price of US$1.25, management illustrates a scenario in which up to 40.0 million new shares could be issued, increasing basic shares outstanding from 184.4 million to 224.4 million (�22% dilution).

Use of proceeds is intentionally broad: working capital, R&D (including ExacTcell� and Tevogen.AI initiatives), capital expenditures, debt repayment, M&A, and other general corporate purposes. The company retains full discretion over timing and sizing of individual placements.

Balance-sheet impact & dilution. As of March 31 2025 Tevogen reported negative net tangible book value (NTBV) of US$(7.7)m, or US$(0.04) per share. Assuming the full US$50 million raise at US$1.25 per share (less 3% fees and estimated US$70k expenses) NTBV would improve to approximately US$40.7 million, or US$0.18 per share, implying immediate dilution of US$1.07 per share to new investors. Additional dilution is possible from: (i) 500k Series A and 4.54 m Series C preferred conversions; (ii) 1.14 m vested RSUs; and (iii) future financings.

Key risks disclosed include: substantial additional capital needs ahead of clinical and AI initiatives; potential constraints imposed by outstanding preferred stock and loan agreements; broad management discretion over proceeds; market overhang from continuous ATM issuance; and the possibility that financing may not be available on acceptable terms, jeopardising ongoing operations.

Strategic context. The facility provides funding flexibility without the execution risk or discount typically associated with overnight offerings, yet continuous issuance could pressure the share price given average trading volumes and the relatively low US$1.25 stock price. Operational execution in advancing TVGN 489 and other pipeline assets remains critical to justify ongoing dilution.

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) ha presentato un supplemento al prospetto Rule 424(b)(5) per istituire un programma di equity at-the-market (ATM) da 50 milioni di dollari USA tramite A.G.P./Alliance Global Partners. Secondo l'accordo di vendita del 3 luglio 2025, A.G.P. agirà come agente di vendita con impegno di massimo sforzo e riceverà una commissione del 3,0% sui proventi lordi. Non è richiesto un prelievo minimo e i proventi non saranno depositati in escrow.

Il programma consente a Tevogen di emettere azioni ordinarie primarie (valore nominale $0,0001) di volta in volta ai prezzi di mercato correnti. Al prezzo di chiusura del 2 luglio 2025 di 1,25 USD, la direzione illustra uno scenario in cui potrebbero essere emesse fino a 40 milioni di nuove azioni, aumentando le azioni ordinarie in circolazione da 184,4 milioni a 224,4 milioni (circa 22% di diluizione).

Utilizzo dei proventi è volutamente ampio: capitale circolante, R&S (inclusi i progetti ExacTcell� e Tevogen.AI), spese in conto capitale, rimborso debiti, fusioni e acquisizioni e altre finalità aziendali generali. La società mantiene piena discrezionalità sul momento e sull'entità delle singole emissioni.

Impatto sul bilancio e diluizione. Al 31 marzo 2025 Tevogen ha riportato un valore netto tangibile negativo (NTBV) di -7,7 milioni di USD, ovvero -0,04 USD per azione. Assumendo la raccolta completa di 50 milioni di USD a 1,25 USD per azione (meno il 3% di commissioni e circa 70.000 USD di spese), l'NTBV migliorerebbe a circa 40,7 milioni di USD, ovvero 0,18 USD per azione, implicando una diluizione immediata di 1,07 USD per azione per i nuovi investitori. Ulteriore diluizione potrebbe derivare da: (i) conversioni di 500.000 azioni Serie A e 4,54 milioni Serie C privilegiate; (ii) 1,14 milioni di RSU maturati; e (iii) future operazioni di finanziamento.

Principali rischi comunicati includono: elevati fabbisogni di capitale prima delle iniziative cliniche e AI; possibili vincoli derivanti da azioni privilegiate e accordi di prestito in essere; ampia discrezionalità della direzione sull’uso dei proventi; pressione sul mercato dovuta all’emissione continua ATM; e la possibilità che i finanziamenti non siano disponibili a condizioni accettabili, mettendo a rischio le operazioni correnti.

Contesto strategico. Il programma offre flessibilità di finanziamento senza il rischio di esecuzione o lo sconto tipico delle offerte overnight, tuttavia l’emissione continua potrebbe esercitare pressione sul prezzo delle azioni dato il volume medio di scambi e il prezzo relativamente basso di 1,25 USD. L’esecuzione operativa nel progresso di TVGN 489 e altri asset pipeline rimane fondamentale per giustificare la diluizione continua.

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) ha presentado un suplemento al prospecto bajo la Regla 424(b)(5) para establecer un programa de acciones at-the-market (ATM) por 50 millones de dólares estadounidenses a través de A.G.P./Alliance Global Partners. Según el Acuerdo de Venta del 3 de julio de 2025, A.G.P. actuará como agente de ventas bajo el mejor esfuerzo y recibirá una comisión del 3,0% sobre los ingresos brutos. No se requiere un desembolso mínimo y los ingresos no se colocarán en fideicomiso.

El programa permite a Tevogen emitir acciones comunes primarias (valor nominal $0.0001) ocasionalmente a precios de mercado vigentes. Al precio de cierre del 2 de julio de 2025 de 1,25 USD, la dirección ilustra un escenario en el que se podrían emitir hasta 40 millones de nuevas acciones, aumentando las acciones básicas en circulación de 184,4 millones a 224,4 millones (�22% de dilución).

Uso de los ingresos es intencionadamente amplio: capital de trabajo, I+D (incluyendo iniciativas ExacTcell� y Tevogen.AI), gastos de capital, pago de deuda, fusiones y adquisiciones, y otros propósitos corporativos generales. La compañía mantiene plena discreción sobre el momento y tamaño de las colocaciones individuales.

Impacto en el balance y dilución. Al 31 de marzo de 2025, Tevogen reportó un valor contable tangible neto (NTBV) negativo de (7,7) millones de USD, o (0,04) USD por acción. Suponiendo la recaudación completa de 50 millones de USD a 1,25 USD por acción (menos 3% de comisiones y aproximadamente 70,000 USD en gastos), el NTBV mejoraría a aproximadamente 40,7 millones de USD, o 0,18 USD por acción, lo que implica una dilución inmediata de 1,07 USD por acción para los nuevos inversores. Se podría producir dilución adicional por: (i) conversiones de 500,000 Series A y 4,54 millones Series C preferentes; (ii) 1,14 millones de RSU adquiridas; y (iii) futuras financiaciones.

Riesgos clave divulgados incluyen: necesidades sustanciales adicionales de capital antes de las iniciativas clínicas y de IA; posibles limitaciones impuestas por acciones preferentes y acuerdos de préstamo vigentes; amplia discreción de la dirección sobre los ingresos; presión en el mercado por la emisión continua ATM; y la posibilidad de que la financiación no esté disponible en términos aceptables, poniendo en riesgo las operaciones en curso.

Contexto estratégico. El programa ofrece flexibilidad financiera sin el riesgo de ejecución o descuento típicos de las ofertas nocturnas, pero la emisión continua podría presionar el precio de las acciones dado el volumen promedio de negociación y el precio relativamente bajo de 1,25 USD. La ejecución operativa en el avance de TVGN 489 y otros activos en cartera sigue siendo clave para justificar la dilución continua.

Tevogen Bio Holdings Inc. (나스�: TVGN)은 A.G.P./Alliance Global Partners� 통해 5,000� 달러 규모� at-the-market(ATM) 주식 프로그램� 설정하는 Rule 424(b)(5) 보충 설명서를 제출했습니다. 2025� 7� 3� 판매 계약� 따라 A.G.P.� 최선� 노력으로 판매 대리인 역할� 하며 � 수익� 3.0% 수수료를 받습니다. 최소 인출 금액은 없으� 수익금은 에스크로� 예치되지 않습니다.

� 프로그램은 Tevogen� 시가� 따라 기본 보통�(액면가 $0.0001)� 수시� 발행� � 있도� 합니�. 2025� 7� 2� 종가� 1.25달러 기준으로 경영진은 최대 4,000� 주의 신주� 발행� � 있는 시나리오� 제시했으�, 기본 발행 주식 수가 1� 8,440� 주에� 2� 2,440� 주로 � 22% 희석� � 있음� 보여줍니�.

수익� 사용은 의도적으� 광범위하�: 운전자본, 연구개발(ExacTcell� � Tevogen.AI 프로젝트 포함), 자본 지�, 부� 상환, 인수합병 � 기타 일반 기업 목적� 사용됩니�. 회사� 개별 배치� 시기와 규모� 대� 전적� 재량권을 보유합니�.

재무 영향 � 희석. 2025� 3� 31� 기준 Tevogen은 순유형자산장부가�(NTBV)가 마이너스 770� 달러, 주당 -0.04달러� 보고했습니다. 1주당 1.25달러� 5,000� 달러 전액 조달(3% 수수� � � 7� 달러 비용 제외)� 가정하� NTBV� � 4,070� 달러, 주당 0.18달러� 개선되어 신규 투자자에게는 즉각적으� 주당 1.07달러� 희석� 발생합니�. 추가 희석은 다음에서 발생� � 있습니다: (i) 50� 주의 시리� A � 454� 주의 시리� C 우선� 전환; (ii) 114� 주의 베스팅된 RSU; (iii) 미래 자금 조달.

주요 위험 공시에는 임상 � AI 이니셔티� 이전� 상당� 추가 자본 필요�, 미결 우선� � 대� 계약� 따른 잠재� 제약, 수익금에 대� 경영진의 광범위한 재량�, 지속적� ATM 발행� 따른 시장 부�, 그리� 자금 조달� 적절� 조건으로 이루어지지 않을 가능성으로 인해 운영� 위태로워� 위험� 포함됩니�.

전략� 맥락. � 프로그램은 일회� 공모� 흔히 수반되는 실행 위험이나 할인 없이 자금 조달 유연성을 제공하지�, 평균 거래량과 상대적으� 낮은 1.25달러 주가� 고려� � 지속적� 발행은 주가� 압박� 가� � 있습니다. TVGN 489 � 기타 파이프라� 자산� 운영 실행� 지속적� 희석� 정당화하� � 매우 중요합니�.

Tevogen Bio Holdings Inc. (Nasdaq : TVGN) a déposé un supplément de prospectus Rule 424(b)(5) établissant un programme d’actions at-the-market (ATM) de 50 millions de dollars US via A.G.P./Alliance Global Partners. Conformément à l’accord de vente du 3 juillet 2025, A.G.P. agira en tant qu’agent de vente sur une base de meilleurs efforts et percevra une commission de 3,0 % sur le produit brut. Aucun tirage minimum n’est requis et les fonds ne seront pas placés en séquestre.

Ce dispositif permet à Tevogen d’émettre des actions ordinaires primaires (valeur nominale 0,0001 $) de temps à autre aux prix du marché en vigueur. Au cours de clôture du 2 juillet 2025 à 1,25 USD, la direction illustre un scénario où jusqu’� 40 millions de nouvelles actions pourraient être émises, augmentant le nombre d’actions de base en circulation de 184,4 millions à 224,4 millions (�22 % de dilution).

Utilisation des fonds est volontairement large : fonds de roulement, R&D (y compris les initiatives ExacTcell� et Tevogen.AI), dépenses en capital, remboursement de dette, fusions et acquisitions, et autres usages généraux d’entreprise. La société conserve une pleine discrétion sur le calendrier et la taille des placements individuels.

Impact sur le bilan et dilution. Au 31 mars 2025, Tevogen affichait une valeur comptable tangible nette (NTBV) négative de (7,7) millions de dollars US, soit (0,04) USD par action. En supposant la levée complète de 50 millions de dollars US à 1,25 USD par action (moins 3 % de commissions et environ 70 000 USD de frais), la NTBV s’améliorerait à environ 40,7 millions de dollars US, soit 0,18 USD par action, impliquant une dilution immédiate de 1,07 USD par action pour les nouveaux investisseurs. Une dilution supplémentaire est possible en raison de : (i) conversions de 500 000 actions privilégiées de série A et 4,54 millions de série C ; (ii) 1,14 million de RSU acquises ; et (iii) futurs financements.

Principaux risques divulgués comprennent : des besoins substantiels supplémentaires de capitaux avant les initiatives cliniques et d’IA ; des contraintes potentielles imposées par les actions privilégiées en circulation et les accords de prêt ; une large discrétion de la direction sur l’utilisation des fonds ; une pression sur le marché due à l’émission continue ATM ; et la possibilité que le financement ne soit pas disponible à des conditions acceptables, mettant en péril les opérations en cours.

Contexte stratégique. Ce dispositif offre une flexibilité de financement sans le risque d’exécution ou la décote généralement associés aux offres nocturnes, mais une émission continue pourrait exercer une pression sur le cours de l’action compte tenu des volumes moyens d’échanges et du cours relativement bas de 1,25 USD. L’exécution opérationnelle dans l’avancement de TVGN 489 et d’autres actifs en pipeline reste cruciale pour justifier la dilution continue.

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) hat einen Nachtrag zum Prospekt nach Rule 424(b)(5) eingereicht, um ein 50 Millionen US-Dollar umfassendes at-the-market (ATM) Eigenkapitalprogramm über A.G.P./Alliance Global Partners einzurichten. Gemäß dem Verkaufsvertrag vom 3. Juli 2025 wird A.G.P. als Verkaufsagent auf Best-Effort-Basis fungieren und eine Provision von 3,0 % auf den Bruttoerlös erhalten. Es ist kein Mindestabruf erforderlich und die Erlöse werden nicht treuhänderisch verwahrt.

Das Programm ermöglicht Tevogen, von Zeit zu Zeit primäre Stammaktien (Nennwert 0,0001 USD) zu den jeweils geltenden Marktpreisen auszugeben. Beim Schlusskurs vom 2. Juli 2025 von 1,25 USD veranschaulicht das Management ein Szenario, in dem bis zu 40,0 Millionen neue Aktien ausgegeben werden könnten, was die ausstehenden Basisaktien von 184,4 Millionen auf 224,4 Millionen erhöht (�22 % Verwässerung).

Verwendung der Erlöse ist bewusst breit gefasst: Betriebskapital, F&E (einschließlich ExacTcell�- und Tevogen.AI-Initiativen), Investitionsausgaben, Schuldenrückzahlung, Fusionen & Übernahmen und andere allgemeine Unternehmenszwecke. Das Unternehmen behält sich volle Entscheidungsfreiheit hinsichtlich Zeitpunkt und Umfang einzelner Platzierungen vor.

Bilanzielle Auswirkungen & Verwässerung. Zum 31. März 2025 meldete Tevogen einen negativen Netto-Sachanlagenbuchwert (NTBV) von -7,7 Mio. USD bzw. -0,04 USD je Aktie. Bei vollständiger Kapitalaufnahme von 50 Mio. USD zu 1,25 USD je Aktie (abzüglich 3 % Gebühren und geschätzten 70.000 USD Kosten) würde sich der NTBV auf etwa 40,7 Mio. USD bzw. 0,18 USD je Aktie verbessern, was eine sofortige Verwässerung von 1,07 USD je Aktie für neue Investoren bedeutet. Weitere Verwässerungen sind möglich durch: (i) Umwandlungen von 500.000 Series A und 4,54 Mio. Series C Vorzugsaktien; (ii) 1,14 Mio. ausgeübte RSUs; und (iii) zukünftige Finanzierungen.

Wesentliche offengelegte Risiken umfassen: erheblichen zusätzlichen Kapitalbedarf vor klinischen und KI-Initiativen; potenzielle Beschränkungen durch ausstehende Vorzugsaktien und Darlehensverträge; weitreichenden Ermessensspielraum des Managements bei der Verwendung der Erlöse; Marktdruck durch kontinuierliche ATM-Emissionen; und die Möglichkeit, dass Finanzierungen nicht zu akzeptablen Bedingungen verfügbar sind, was den laufenden Betrieb gefährden könnte.

Strategischer Kontext. Das Programm bietet Finanzierungsspielraum ohne das Ausführungsrisiko oder den Abschlag, die typischerweise mit Overnight-Angeboten verbunden sind. Dennoch könnte die kontinuierliche Emission angesichts der durchschnittlichen Handelsvolumina und des relativ niedrigen Aktienkurses von 1,25 USD den Aktienkurs unter Druck setzen. Die operative Umsetzung bei der Weiterentwicklung von TVGN 489 und anderen Pipeline-Assets bleibt entscheidend, um die fortlaufende Verwässerung zu rechtfertigen.

Positive
  • Enhanced liquidity: ATM facility enables access to up to US$50 million on flexible terms, improving cash runway.
  • Book-value improvement: Full utilisation could swing net tangible book value from negative US$7.7 m to positive ≈US$40.7 m.
  • Standard commission: 3% agency fee aligns with prevailing market rates, limiting transaction costs.
Negative
  • Dilution risk: Up to 40 m new shares (~22 % of current float) plus preferred conversions may materially dilute existing holders.
  • Negative starting equity: Pre-offering NTBV is negative, highlighting current balance-sheet weakness.
  • Financing dependence: Filing states substantial additional capital will still be required, signalling ongoing funding gap.
  • Market overhang: Continuous ATM sales may exert downward pressure on share price, especially at ~US$1.25 level.

Insights

TL;DR — Flexible US$50 m ATM boosts liquidity but materially dilutes shareholders; neutral to slightly negative near-term.

The ATM program strengthens Tevogen’s cash options at a time when its NTBV is negative and R&D spend is ramping. Because issuance occurs at market prices, pricing risk is reduced, yet the illustrative 40 million-share scenario adds ~22 % to the float, compressing per-share metrics and likely capping upside until clinical catalysts emerge. Improving NTBV to ~US$0.18 per share is constructive, but investors absorb US$1.07 immediate dilution. The 3 % fee is standard. Overall impact is modestly dilutive with limited operational change; therefore I assign a neutral (0) rating.

TL;DR — Standard ATM mechanics; provides runway yet signals persistent funding gap.

ATM structures suit micro-cap biotech issuers seeking opportunistic taps, but persistent reliance can create an overhang and erode investor confidence. Tevogen’s broad use-of-funds language and existing preferred-stock overhang suggest the balance sheet remains fragile. While management gains agility, markets may discount shares further to accommodate supply. Given typical biotech risk capital appetite, I view the announcement as not materially value-accretive nor catastrophic, meriting a neutral (0) impact assessment.

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) ha presentato un supplemento al prospetto Rule 424(b)(5) per istituire un programma di equity at-the-market (ATM) da 50 milioni di dollari USA tramite A.G.P./Alliance Global Partners. Secondo l'accordo di vendita del 3 luglio 2025, A.G.P. agirà come agente di vendita con impegno di massimo sforzo e riceverà una commissione del 3,0% sui proventi lordi. Non è richiesto un prelievo minimo e i proventi non saranno depositati in escrow.

Il programma consente a Tevogen di emettere azioni ordinarie primarie (valore nominale $0,0001) di volta in volta ai prezzi di mercato correnti. Al prezzo di chiusura del 2 luglio 2025 di 1,25 USD, la direzione illustra uno scenario in cui potrebbero essere emesse fino a 40 milioni di nuove azioni, aumentando le azioni ordinarie in circolazione da 184,4 milioni a 224,4 milioni (circa 22% di diluizione).

Utilizzo dei proventi è volutamente ampio: capitale circolante, R&S (inclusi i progetti ExacTcell� e Tevogen.AI), spese in conto capitale, rimborso debiti, fusioni e acquisizioni e altre finalità aziendali generali. La società mantiene piena discrezionalità sul momento e sull'entità delle singole emissioni.

Impatto sul bilancio e diluizione. Al 31 marzo 2025 Tevogen ha riportato un valore netto tangibile negativo (NTBV) di -7,7 milioni di USD, ovvero -0,04 USD per azione. Assumendo la raccolta completa di 50 milioni di USD a 1,25 USD per azione (meno il 3% di commissioni e circa 70.000 USD di spese), l'NTBV migliorerebbe a circa 40,7 milioni di USD, ovvero 0,18 USD per azione, implicando una diluizione immediata di 1,07 USD per azione per i nuovi investitori. Ulteriore diluizione potrebbe derivare da: (i) conversioni di 500.000 azioni Serie A e 4,54 milioni Serie C privilegiate; (ii) 1,14 milioni di RSU maturati; e (iii) future operazioni di finanziamento.

Principali rischi comunicati includono: elevati fabbisogni di capitale prima delle iniziative cliniche e AI; possibili vincoli derivanti da azioni privilegiate e accordi di prestito in essere; ampia discrezionalità della direzione sull’uso dei proventi; pressione sul mercato dovuta all’emissione continua ATM; e la possibilità che i finanziamenti non siano disponibili a condizioni accettabili, mettendo a rischio le operazioni correnti.

Contesto strategico. Il programma offre flessibilità di finanziamento senza il rischio di esecuzione o lo sconto tipico delle offerte overnight, tuttavia l’emissione continua potrebbe esercitare pressione sul prezzo delle azioni dato il volume medio di scambi e il prezzo relativamente basso di 1,25 USD. L’esecuzione operativa nel progresso di TVGN 489 e altri asset pipeline rimane fondamentale per giustificare la diluizione continua.

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) ha presentado un suplemento al prospecto bajo la Regla 424(b)(5) para establecer un programa de acciones at-the-market (ATM) por 50 millones de dólares estadounidenses a través de A.G.P./Alliance Global Partners. Según el Acuerdo de Venta del 3 de julio de 2025, A.G.P. actuará como agente de ventas bajo el mejor esfuerzo y recibirá una comisión del 3,0% sobre los ingresos brutos. No se requiere un desembolso mínimo y los ingresos no se colocarán en fideicomiso.

El programa permite a Tevogen emitir acciones comunes primarias (valor nominal $0.0001) ocasionalmente a precios de mercado vigentes. Al precio de cierre del 2 de julio de 2025 de 1,25 USD, la dirección ilustra un escenario en el que se podrían emitir hasta 40 millones de nuevas acciones, aumentando las acciones básicas en circulación de 184,4 millones a 224,4 millones (�22% de dilución).

Uso de los ingresos es intencionadamente amplio: capital de trabajo, I+D (incluyendo iniciativas ExacTcell� y Tevogen.AI), gastos de capital, pago de deuda, fusiones y adquisiciones, y otros propósitos corporativos generales. La compañía mantiene plena discreción sobre el momento y tamaño de las colocaciones individuales.

Impacto en el balance y dilución. Al 31 de marzo de 2025, Tevogen reportó un valor contable tangible neto (NTBV) negativo de (7,7) millones de USD, o (0,04) USD por acción. Suponiendo la recaudación completa de 50 millones de USD a 1,25 USD por acción (menos 3% de comisiones y aproximadamente 70,000 USD en gastos), el NTBV mejoraría a aproximadamente 40,7 millones de USD, o 0,18 USD por acción, lo que implica una dilución inmediata de 1,07 USD por acción para los nuevos inversores. Se podría producir dilución adicional por: (i) conversiones de 500,000 Series A y 4,54 millones Series C preferentes; (ii) 1,14 millones de RSU adquiridas; y (iii) futuras financiaciones.

Riesgos clave divulgados incluyen: necesidades sustanciales adicionales de capital antes de las iniciativas clínicas y de IA; posibles limitaciones impuestas por acciones preferentes y acuerdos de préstamo vigentes; amplia discreción de la dirección sobre los ingresos; presión en el mercado por la emisión continua ATM; y la posibilidad de que la financiación no esté disponible en términos aceptables, poniendo en riesgo las operaciones en curso.

Contexto estratégico. El programa ofrece flexibilidad financiera sin el riesgo de ejecución o descuento típicos de las ofertas nocturnas, pero la emisión continua podría presionar el precio de las acciones dado el volumen promedio de negociación y el precio relativamente bajo de 1,25 USD. La ejecución operativa en el avance de TVGN 489 y otros activos en cartera sigue siendo clave para justificar la dilución continua.

Tevogen Bio Holdings Inc. (나스�: TVGN)은 A.G.P./Alliance Global Partners� 통해 5,000� 달러 규모� at-the-market(ATM) 주식 프로그램� 설정하는 Rule 424(b)(5) 보충 설명서를 제출했습니다. 2025� 7� 3� 판매 계약� 따라 A.G.P.� 최선� 노력으로 판매 대리인 역할� 하며 � 수익� 3.0% 수수료를 받습니다. 최소 인출 금액은 없으� 수익금은 에스크로� 예치되지 않습니다.

� 프로그램은 Tevogen� 시가� 따라 기본 보통�(액면가 $0.0001)� 수시� 발행� � 있도� 합니�. 2025� 7� 2� 종가� 1.25달러 기준으로 경영진은 최대 4,000� 주의 신주� 발행� � 있는 시나리오� 제시했으�, 기본 발행 주식 수가 1� 8,440� 주에� 2� 2,440� 주로 � 22% 희석� � 있음� 보여줍니�.

수익� 사용은 의도적으� 광범위하�: 운전자본, 연구개발(ExacTcell� � Tevogen.AI 프로젝트 포함), 자본 지�, 부� 상환, 인수합병 � 기타 일반 기업 목적� 사용됩니�. 회사� 개별 배치� 시기와 규모� 대� 전적� 재량권을 보유합니�.

재무 영향 � 희석. 2025� 3� 31� 기준 Tevogen은 순유형자산장부가�(NTBV)가 마이너스 770� 달러, 주당 -0.04달러� 보고했습니다. 1주당 1.25달러� 5,000� 달러 전액 조달(3% 수수� � � 7� 달러 비용 제외)� 가정하� NTBV� � 4,070� 달러, 주당 0.18달러� 개선되어 신규 투자자에게는 즉각적으� 주당 1.07달러� 희석� 발생합니�. 추가 희석은 다음에서 발생� � 있습니다: (i) 50� 주의 시리� A � 454� 주의 시리� C 우선� 전환; (ii) 114� 주의 베스팅된 RSU; (iii) 미래 자금 조달.

주요 위험 공시에는 임상 � AI 이니셔티� 이전� 상당� 추가 자본 필요�, 미결 우선� � 대� 계약� 따른 잠재� 제약, 수익금에 대� 경영진의 광범위한 재량�, 지속적� ATM 발행� 따른 시장 부�, 그리� 자금 조달� 적절� 조건으로 이루어지지 않을 가능성으로 인해 운영� 위태로워� 위험� 포함됩니�.

전략� 맥락. � 프로그램은 일회� 공모� 흔히 수반되는 실행 위험이나 할인 없이 자금 조달 유연성을 제공하지�, 평균 거래량과 상대적으� 낮은 1.25달러 주가� 고려� � 지속적� 발행은 주가� 압박� 가� � 있습니다. TVGN 489 � 기타 파이프라� 자산� 운영 실행� 지속적� 희석� 정당화하� � 매우 중요합니�.

Tevogen Bio Holdings Inc. (Nasdaq : TVGN) a déposé un supplément de prospectus Rule 424(b)(5) établissant un programme d’actions at-the-market (ATM) de 50 millions de dollars US via A.G.P./Alliance Global Partners. Conformément à l’accord de vente du 3 juillet 2025, A.G.P. agira en tant qu’agent de vente sur une base de meilleurs efforts et percevra une commission de 3,0 % sur le produit brut. Aucun tirage minimum n’est requis et les fonds ne seront pas placés en séquestre.

Ce dispositif permet à Tevogen d’émettre des actions ordinaires primaires (valeur nominale 0,0001 $) de temps à autre aux prix du marché en vigueur. Au cours de clôture du 2 juillet 2025 à 1,25 USD, la direction illustre un scénario où jusqu’� 40 millions de nouvelles actions pourraient être émises, augmentant le nombre d’actions de base en circulation de 184,4 millions à 224,4 millions (�22 % de dilution).

Utilisation des fonds est volontairement large : fonds de roulement, R&D (y compris les initiatives ExacTcell� et Tevogen.AI), dépenses en capital, remboursement de dette, fusions et acquisitions, et autres usages généraux d’entreprise. La société conserve une pleine discrétion sur le calendrier et la taille des placements individuels.

Impact sur le bilan et dilution. Au 31 mars 2025, Tevogen affichait une valeur comptable tangible nette (NTBV) négative de (7,7) millions de dollars US, soit (0,04) USD par action. En supposant la levée complète de 50 millions de dollars US à 1,25 USD par action (moins 3 % de commissions et environ 70 000 USD de frais), la NTBV s’améliorerait à environ 40,7 millions de dollars US, soit 0,18 USD par action, impliquant une dilution immédiate de 1,07 USD par action pour les nouveaux investisseurs. Une dilution supplémentaire est possible en raison de : (i) conversions de 500 000 actions privilégiées de série A et 4,54 millions de série C ; (ii) 1,14 million de RSU acquises ; et (iii) futurs financements.

Principaux risques divulgués comprennent : des besoins substantiels supplémentaires de capitaux avant les initiatives cliniques et d’IA ; des contraintes potentielles imposées par les actions privilégiées en circulation et les accords de prêt ; une large discrétion de la direction sur l’utilisation des fonds ; une pression sur le marché due à l’émission continue ATM ; et la possibilité que le financement ne soit pas disponible à des conditions acceptables, mettant en péril les opérations en cours.

Contexte stratégique. Ce dispositif offre une flexibilité de financement sans le risque d’exécution ou la décote généralement associés aux offres nocturnes, mais une émission continue pourrait exercer une pression sur le cours de l’action compte tenu des volumes moyens d’échanges et du cours relativement bas de 1,25 USD. L’exécution opérationnelle dans l’avancement de TVGN 489 et d’autres actifs en pipeline reste cruciale pour justifier la dilution continue.

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) hat einen Nachtrag zum Prospekt nach Rule 424(b)(5) eingereicht, um ein 50 Millionen US-Dollar umfassendes at-the-market (ATM) Eigenkapitalprogramm über A.G.P./Alliance Global Partners einzurichten. Gemäß dem Verkaufsvertrag vom 3. Juli 2025 wird A.G.P. als Verkaufsagent auf Best-Effort-Basis fungieren und eine Provision von 3,0 % auf den Bruttoerlös erhalten. Es ist kein Mindestabruf erforderlich und die Erlöse werden nicht treuhänderisch verwahrt.

Das Programm ermöglicht Tevogen, von Zeit zu Zeit primäre Stammaktien (Nennwert 0,0001 USD) zu den jeweils geltenden Marktpreisen auszugeben. Beim Schlusskurs vom 2. Juli 2025 von 1,25 USD veranschaulicht das Management ein Szenario, in dem bis zu 40,0 Millionen neue Aktien ausgegeben werden könnten, was die ausstehenden Basisaktien von 184,4 Millionen auf 224,4 Millionen erhöht (�22 % Verwässerung).

Verwendung der Erlöse ist bewusst breit gefasst: Betriebskapital, F&E (einschließlich ExacTcell�- und Tevogen.AI-Initiativen), Investitionsausgaben, Schuldenrückzahlung, Fusionen & Übernahmen und andere allgemeine Unternehmenszwecke. Das Unternehmen behält sich volle Entscheidungsfreiheit hinsichtlich Zeitpunkt und Umfang einzelner Platzierungen vor.

Bilanzielle Auswirkungen & Verwässerung. Zum 31. März 2025 meldete Tevogen einen negativen Netto-Sachanlagenbuchwert (NTBV) von -7,7 Mio. USD bzw. -0,04 USD je Aktie. Bei vollständiger Kapitalaufnahme von 50 Mio. USD zu 1,25 USD je Aktie (abzüglich 3 % Gebühren und geschätzten 70.000 USD Kosten) würde sich der NTBV auf etwa 40,7 Mio. USD bzw. 0,18 USD je Aktie verbessern, was eine sofortige Verwässerung von 1,07 USD je Aktie für neue Investoren bedeutet. Weitere Verwässerungen sind möglich durch: (i) Umwandlungen von 500.000 Series A und 4,54 Mio. Series C Vorzugsaktien; (ii) 1,14 Mio. ausgeübte RSUs; und (iii) zukünftige Finanzierungen.

Wesentliche offengelegte Risiken umfassen: erheblichen zusätzlichen Kapitalbedarf vor klinischen und KI-Initiativen; potenzielle Beschränkungen durch ausstehende Vorzugsaktien und Darlehensverträge; weitreichenden Ermessensspielraum des Managements bei der Verwendung der Erlöse; Marktdruck durch kontinuierliche ATM-Emissionen; und die Möglichkeit, dass Finanzierungen nicht zu akzeptablen Bedingungen verfügbar sind, was den laufenden Betrieb gefährden könnte.

Strategischer Kontext. Das Programm bietet Finanzierungsspielraum ohne das Ausführungsrisiko oder den Abschlag, die typischerweise mit Overnight-Angeboten verbunden sind. Dennoch könnte die kontinuierliche Emission angesichts der durchschnittlichen Handelsvolumina und des relativ niedrigen Aktienkurses von 1,25 USD den Aktienkurs unter Druck setzen. Die operative Umsetzung bei der Weiterentwicklung von TVGN 489 und anderen Pipeline-Assets bleibt entscheidend, um die fortlaufende Verwässerung zu rechtfertigen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Meyer Daniel Harris

(Last) (First) (Middle)
C/O SHAKE SHACK INC.
225 VARICK STREET, SUITE 301

(Street)
NEW YORK NY 10014

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Shake Shack Inc. [ SHAK ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock, par value $0.001 per share 07/01/2025 S 3,400 D $137.7786 364,584(1)(6) I By Trust(7)
Class A Common Stock, par value $0.001 per share 07/01/2025 S 5,200 D $138.436 359,384(2)(6) I By Trust(7)
Class A Common Stock, par value $0.001 per share 07/01/2025 S 6,377 D $140.0103 353,007(3)(6) I By Trust(7)
Class A Common Stock, par value $0.001 per share 07/01/2025 S 823 D $140.3555 352,184(4)(6) I By Trust(7)
Class A Common Stock, par value $0.001 per share 07/02/2025 S 14,200 D $140.3137 337,984(5)(6) I By Trust(7)
Class A Common Stock, par value $0.001 per share 1,279,107 I By Trust(8)
Class A Common Stock, par value $0.001 per share 11,319 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
Meyer Daniel Harris

(Last) (First) (Middle)
C/O SHAKE SHACK INC.
225 VARICK STREET, SUITE 301

(Street)
NEW YORK NY 10014

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
DANIEL H. MEYER 2012 GIFT TRUST U/A/D 10/31/12

(Last) (First) (Middle)
C/O SHAKE SHACK, INC.
225 VARICK STREET, SUITE 301

(Street)
NEW YORK NY 10014

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
MEYER AUDREY H

(Last) (First) (Middle)
C/O SHAKE SHACK INC.
225 VARICK STREET, SUITE 301

(Street)
NEW YORK NY 10014

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
McQuinn Michael C

(Last) (First) (Middle)
C/O SHAKE SHACK INC.
225 VARICK STREET, SUITE 301

(Street)
NEW YORK NY 10014

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. The transaction was executed in multiple trades at prices ranging from $137.16 to $138.15. The price reported above reflects the weighted average sales price.
2. The transaction was executed in multiple trades at prices ranging from $138.17 to $138.80. The price reported above reflects the weighted average sales price.
3. The transaction was executed in multiple trades at prices ranging from $139.26 to $140.25. The price reported above reflects the weighted average sales price.
4. The transaction was executed in multiple trades at prices ranging from $140.29 to $140.42. The price reported above reflects the weighted average sales price.
5. The transaction was executed in multiple trades at prices ranging from $140.00 to $140.74. The price reported above reflects the weighted average sales price.
6. The Daniel H. Meyer Investment Trust (the "Investment Trust") hereby undertakes to provide upon request to the SEC staff, Shake Shack Inc. (the "Issuer") or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
7. Shares of Class A Stock of the Issuer were disposed of by Mr. Meyer through the Investment Trust pursuant to a Rule 10b5-1 trading plan entered into on November 15, 2024. Mr. Meyer is the grantor, trustee and beneficiary of the Investment Trust. Mr. Meyer disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
8. Represents shares of Class A Stock of the Issuer held by the DHM 2012 Gift Trust (the "Gift Trust"), of which Mr. Meyer's spouse is a co-trustee and beneficiary of the Gift Trust. Mr. McQuinn is a co-trustee. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of such Reporting Persons' pecuniary interest therein.
/s/ Ronald Palmese, Jr., Esq. - Attorney-in-Fact for Daniel Harris Meyer 07/03/2025
/s/ Ronald Palmese, Jr., Esq. - Attorney-in-Fact for DHM 2012 Gift Trust U/A/D 10/31/12 07/03/2025
/s/ Ronald Palmese, Jr., Esq. - Attorney-in-Fact for Audrey H. Meyer 07/03/2025
/s/ Ronald Palmese, Jr., Esq. - Attorney-in-Fact for Michael C. McQuinn 07/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What is Tevogen Bio Holdings (TVGN) offering under the new prospectus supplement?

The company can sell up to US$50 million of common stock through an at-the-market program administered by A.G.P./Alliance Global Partners.

How much will A.G.P. earn for acting as sales agent?

A.G.P. will receive a 3.0 % commission on the gross proceeds of each share sold under the ATM agreement.

What is the potential dilution to existing TVGN shareholders?

If the full US$50 million is raised at US$1.25 per share, up to 40 million new shares could be issued, increasing the share count by about 22 %.

How will Tevogen use the proceeds from the ATM sales?

Management lists general corporate purposes such as working capital, R&D, capital expenditures, debt repayment, acquisitions and other investments.

What is the impact on net tangible book value (NTBV)?

NTBV would improve from US$(0.04) per share to approximately US$0.18 per share after the full raise, but new investors face US$1.07 per-share dilution.

Is there a minimum amount that must be sold under the ATM?

No. The Sales Agreement imposes no minimum drawdown; Tevogen may issue shares at its discretion.
Shake Shack Inc

NYSE:SHAK

SHAK Rankings

SHAK Latest News

SHAK Latest SEC Filings

SHAK Stock Data

5.57B
38.39M
5.17%
101.48%
10.42%
Restaurants
Retail-eating & Drinking Places
United States
NEW YORK